Reconsidering empirical cotrimoxazole prophylaxis for infants exposed to HIV infection

Bulletin of the World Health Organization

Volumn 82, Issue 4, 2004, Pages 290-297

  Gill, Christopher J ^a   Sabin, Lora L ^a   Tham, Joseph ^a   Hamer, Davidson H ^b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS related opportunistic infections drug therapy; Disease transmission, Vertical; Drug resistance, Microbial; HIV infections complications; Pneumonia, Pneumocystis drug therapy; Trimethoprim sulfamethoxazole combination therapeutic use adverse effects

Indexed keywords

ANTIMALARIAL AGENT; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; COTRIMOXAZOLE; FANSIDAR; MACROLIDE; PENICILLIN G; TETRACYCLINE DERIVATIVE;

CHILD HEALTH; DISEASE CONTROL; DRUG RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS;

ANEMIA; ANTIBIOTIC RESISTANCE; ARTICLE; BREAST FEEDING; EMPIRICISM; FEVER; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; PNEUMOCYSTIS PNEUMONIA; PROPHYLAXIS; RASH; STEVENS JOHNSON SYNDROME; WORLD HEALTH ORGANIZATION;

AFRICA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; BREAST FEEDING; CHEMOPREVENTION; DRUG RESISTANCE; HUMANS; INFANT; INFANT, NEWBORN; PNEUMONIA, PNEUMOCYSTIS; PRACTICE GUIDELINES; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; WORLD HEALTH ORGANIZATION;

EID: 2342541584     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. UNAIDS. UNAIDS/WHO hail consensus on use of cotrimoxazole for prevention of HIV-related infections in Africa, 2000. http://www.unaids.org/whatsnew/press/eng/pressarc00/geneva050400.html
2. Moodley D, Bobat RA, Coutsoudis A, Coovadia HM. Predicting perinatal human immunodeficiency virus infection by antibody patterns. Pediatric Infectious Disease 1995;14:850-2.
3. Santmyire BR. Vertical transmission of HIV from mother to child in sub-Saharan Africa: modes of transmission and methods for prevention. Obstetrical and Gynecological Survey 2001;56:306-12.
4. Berer M. HIV/AIDS, sexual and reproductive health at AIDS 2000, Durban. Reproductive Health Matters 2000;8:160-9.
5. Duliege AM, Messiah A, Blanche S, Tardieu M, Griscelli C, Spira A. Natural history of human immunodeficiency virus type 1 infection in children: prognostic value of laboratory tests on the bimodal progression of the disease. Pediatric Infectious Disease 1992;11:630-5.
6. Children born to women with HIV-1 infection: natural history and risk of transmission. European Collaborative Study. Lancet 1991;337:253-60.
7. Scott GB, Hutto C, Makuch RW, Mastrucci MT, O'Connor T, Mitchell CD, et al. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. New England Journal of Medicine 1989;321:1791-6.
8. Spira R, Lepage P, Msellati P, Van De Perre P, Leroy V, Simonon A, et al. Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Mother-to-Child HIV-1 Transmission Study Group. Pediatrics 1999;104:e56.
9. Taha TE, Kumwenda NI, Broadhead RL, Hoover DR, Graham SM, Van Der Hoven L, et al. Mortality after the first year of life among human immunodeficiency virus type 1-infected and uninfected children. Pediatric Infectious Disease 1999;18:689-94.
10. Boerma JT, Nunn AJ, Whitworth JA. Mortality impact of the AIDS epidemic: evidence from community studies in less developed countries. AIDS 1998;12 Suppl 1:S3-14.
11. Simonds RJ, Oxtoby MJ, Caldwell MB, Gwinn ML, Rogers MF. Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection. JAMA 1993;270:470-3.
12. Murray CJ, Lopez AD. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science 1996;274:740-3.
13. Johnson JP, Nair P, Hines SE, Seiden SW, Alger L, Revie DR, et al. Natural history and serologic diagnosis of infants born to human immunodeficiency virus-infected women. American Journal of Diseases of Children 1989;143:1147-53.
14. Mallolas J, Zamora L, Gatell JM, Miro JM, Vernet E, Valls ME, et al. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine. AIDS 1993;7:59-64.
15. Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet 1999;353:1469-75.
16. Anglaret X, Chene G, Attia A, Toure S, Lafont S, Combe P, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 1999;353:1463-8.
17. Maynart M, Lievre L, Sow PS, Kony S, Gueye NF, Bassene E, et al. Primary prevention with cotrimoxazole for HIV-1-infected adults: results of the pilot study in Dakar, Senegal. Journal of Acquired Immune Deficiciency Syndromes 2001;26:130-6.
18. Thea DM, Lambert G, Weedon J, Matheson PB, Abrams EJ, Bamji M, et al. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group. Pediatrics 1996;97:59-64.
19. Chokephaibulkit K, Chuachoowong R, Chotpitayasunondh T, Chearskul S, Vanprapar N, Waranawat N, et al. Evaluating a new strategy for prophylaxis to prevent Pneumocystis carinii pneumonia in HIV-exposed infants in Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. AIDS 2000;14:1563-9.
20. Zar HJ, Hanslo D, Tannenbaum E, Klein M, Argent A, Eley B, et al. Aetiology and outcome of pneumonia in human immunodeficiency virus-infected children hospitalized in South Africa. Acta Paediatrica 2001;90:119-25.
21. Ruffini DD, Madhi SA. The high burden of Pneumocystis carinii pneumonia in African HIV-1-infected children hospitalized for severe pneumonia. AIDS 2002;16:105-12.
22. Madhi SA, Cutland C, Ismail K, O'Reilly C, Mancha A, Klugman KP. Ineffectiveness of trimethoprim-sulfamethoxazole prophylaxis and the importance of bacterial and viral coinfections in African children with Pneumocystis carinii pneumonia. Clinical Infectious Diseases 2002;35:1120-6.
23. May T, Beuscart C, Reynes J, Marchou B, Leclercq P, Borsa Lebas F, et al. Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. LFPMI Study Group. Ligue Française de Prévention des Maladies Infectieuses. Journal of Acquired Immune Deficiency Syndromes 1994;7:457-62.
24. Martin MA, Cox PH, Beck K, Styer CM, Beall GN. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Archives of Internal Medicine 1992;152:523-8.
25. Fisher RG, Nageswaran S, Valentine ME, McKinney RE, Jr. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole. AIDS Patient Care and STDs 2001;15:263-9.
26. Anglin DL, Siegel JD, Pacini DL, Smith SJ, Adams G, Buchanan GR. Effect of penicillin prophylaxis on nasopharyngeal colonization with Streptococcus pneumoniae in children with sickle cell anemia. Journal of Pediatrics 1984;104:18-22.
27. Sandock DS, Gothe BG, Bodner DR. Trimethoprim-sulfamethoxazole prophylaxis against urinary tract infection in the chronic spinal cord injury patient. Paraplegia 1995;33:156-60.
28. Brook I, Gober AE. Prophylaxis with amoxidllin or sulfisoxazole for otitis media: effect on the recovery of penicillin-resistant bacteria from children. Clinical Infectious Diseases 1996;22:143-5.
29. Meynard JL, Barbut F, Blum L, Guiguet M, Chouaid C, Meyohas MC, et al. Risk factors for isolation of Streptococcus pneumoniae with decreased susceptibility to penicillin G from patients infected with human immunodeficiency virus. Clinical Infectious Diseases 1996;22:437-40.
30. Reichler MR, Allphin AA, Breiman RF, Schreiber JR, Arnold JE, McDougal LK, et al. The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio. Journal of Infectious Diseases 1992;166:1346-53.
31. Melander E, Ekdahl K, Hansson HB, Kamme C, Laurell M, Nilsson P, et al. Introduction and clonal spread of penicillin- and trimethoprim/sulfamethoxazole-resistant Streptococcus pneumoniae, serotype 9V, in southern Sweden. Microbial Drug Resistance 1998;4:71-8.
32. World Health Organization: Improving Child Health IMCI: the integrated approach. Geneva Switzerland: World Health Organization; 1996, WHO/CHD/97.12 Rev. 1.
33. Feikin DR, Davis M, Nwanyanwu OC, Kazembe PN, Barat LM, Wasas A, et al. Antibiotic resistance and serotype distribution of Streptococcus pneumoniae colonizing rural Malawian children. Pediatric Infectious Disease 2003;22:564-7.
34. Courvalin P, Carlier C. Transposable multiple antibiotic resistance in Streptococcus pneumoniae. Molular and General Genetics 1986;205:291-7.
35. Smith JT, Lewin CS. Mechanisms of antimicrobial resistance and implications for epidemiology. Veterinary Microbiology 1993;35:233-42.
36. Murray CJL, Lopez A., Mathers C, Stein C. The Global Burden of Diseases 2000 Project: aims, methods and data sources. Geneva: World Health Organization; 2001. Global Programme on Evidence for Health Policy Discussion Paper number 36.
37. Vasconcelos KF, Plowe CV, Fontes CJ, Kyle D, Wirth DF, Pereira da Silva LH, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil. Memorias do Instituto Oswaldo Cruz 2000;95:721-8.
38. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. Journal of Infectious Diseases 2002;185:380-8.
39. Iyer JK, Milhous WK, Cortese JF, Kublin JG, Plowe CV. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet 2001;358:1066-7.
40. Whitty CJ, Jaffar S. Plasmodium falciparum cross resistance. Lancet 2002;359:80.
41. Omar SA, Bakari A, Owiti A, Adagu IS, Warhurst DC. Co-trimoxazole compared with sulfadoxine-pyrimethamine in the treatment of uncomplicated malaria in Kenyan children. Transactions of the Royal Society of Tropical Medicine and Hygiene 2001;95:657-60.
42. Daramola OO, Alonso PL, O'Dempsey TJ, Twumasi P, McArdle TF, Greenwood BM. Sensitivity of Plasmodium falciparum in The Gambia to cotrimoxazole. Transactions of the Royal Society of Tropical Medicine and Hygiene 1991;85:345-8.
43. Feikin DR, Dowell SF, Nwanyanwu OC, Klugman KP, Kazembe PN, Barat LM, et al. Increased carriage of trimethoprim/sulfamethoxazole-resistant Streptococcus pneumoniae in Malawian children after treatment for malaria with sulfadoxine/pyrimethamine. Journal of Infectious Diseases 2000;181:1501-5.
44. Snow RW, Omumbo JA, Lowe B, Molyneux CS, Obiero JO, Palmer A, et al. Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet 1997;349:1650-4.
45. Lucas SB, Peacock CS, Hounnou A, Brattegaard K, Koffi K, Honde M, et al. Disease in children infected with HIV in Abidjan, Côte d'Ivoire. BMJ 1996;312:335-8.
46. Ikeogu MO, Wolf B, Mathe S. Pulmonary manifestations in HIV seropositivity and malnutrition in Zimbabwe. Archives of Disease in Childhood 1997;76:124-8.
47. Jeena PM, Coovadia HM, Chrystal V. Pneumocystis carinii and cytomegalovirus infections in severely ill, HIV-infected African infants. Annals of Tropical Paediatrics 1996;16:361-8.
48. Nathoo KJ, Gondo M, Gwanzura L, Mhlanga BR, Mavetera T, Mason PR, Fatal Pneumocystis carinii pneumonia in HIV-seropositive infants in Harare, Zimbabwe. Transactions of the Royal Society of Tropical Medicine and Hygiene 2001;95:37-9.
49. Chintu C, Mudenda V, Lucas S, Nunn A, Lishimpi K, Maswahu D, et al. Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet 2002;360:985-90.
50. Ansari NA, Kombe AH, Kenyon TA, Mazhani L, Binkin N, Tappero JW, et al. Pathology and causes of death in a series of human immunodeficiency virus-positive and -negative pediatric referral hospital admissions in Botswana. Pediatric Infectious Disease 2003;22:43-7.
51. Kamiya Y, Mtitimila E, Graham SM, Broadhead RL, Brabin B, Hart CA. Pneumocystis carinii pneumonia in Malawian children. Annals of Tropical Paediatrics 1997;17:121-6.
52. Graham SM, Mtitimila EI, Kamanga HS, Walsh AL, Hart CA, Molyneux ME. Clinical presentation and outcome of Pneumocystis carinii pneumonia in Malawian children. Lancet 2000;355:369-73.